Vedolizumab, a selective α4β7 inhibitor, and Ustekinumab, an IL12/23 inhibitor, are usually given to IBD patients who have failed or who are intolerant of anti-TNF therapy. The gene discussed is TNF; the disease is inflammatory bowel disease.